← Back to Search

Behavioral Intervention

Low-Resistance Training for Pulmonary Hypertension (RESIST-PH Trial)

N/A
Recruiting
Led By Nadine Al-Naamani, MD, MS
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of PAH: idiopathic, heritable, associated with connective tissue disease, congenital heart disease, human immunodeficiency virus, drug- or toxin, or portopulmonary hypertension
Be older than 18 years old
Must not have
Recent hospitalization (within 4 weeks of screening)
Moderate or severe concomitant lung disease: Chronic Obstructive Pulmonary Disease (COPD) or interstitial lung disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of twice per year
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to understand how low-resistance training can improve the quality of life and reduce frailty in individuals with pulmonary arterial hypertension. Low-resistance training is a proven method that may enhance patients'

Who is the study for?
This trial is for individuals with pulmonary arterial hypertension (PAH) who are experiencing frailty. The study aims to include those who can safely perform low-resistance exercises and are looking to improve their quality of life.
What is being tested?
The focus of the trial is on the effects of low-resistance training on patients with PAH. It seeks to determine if this type of exercise can reduce frailty and enhance overall well-being.
What are the potential side effects?
Low-resistance training is generally safe, but may cause muscle soreness or fatigue. People with PAH should monitor for any unusual symptoms like worsening breathlessness during the program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with PAH related to a specific cause.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I was hospitalized within the last 4 weeks.
Select...
I have a serious lung condition like COPD or interstitial lung disease.
Select...
I cannot do certain physical tests or am confined to a wheelchair.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of twice per year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of twice per year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events
Feasibility of Recruitment
Feasibility of Study
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: All subjectsExperimental Treatment1 Intervention
All subjects will participate in the low-resistance training

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,084 Previous Clinical Trials
42,727,028 Total Patients Enrolled
7 Trials studying Pulmonary Arterial Hypertension
256 Patients Enrolled for Pulmonary Arterial Hypertension
Nadine Al-Naamani, MD, MSPrincipal InvestigatorUniversity of Pennsylvania
~13 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top